Study wrapper · #785
Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.
Editor's note
This in-vitro formulation study repurposes the Bowman-Birk protease inhibitor (BBI), co-encapsulating it with semaglutide in hydrogel beads to protect the peptide from digestion for oral delivery. Researchers reported that BBI release inhibited trypsin and extended semaglutide's simulated intestinal residence time from 2.5 to 4 hours, with early BBI release creating a low-protease window for sustained semaglutide release. These are laboratory and simulated-digestion results only, no animals or people, so they demonstrate a delivery concept, not clinical performance or bioavailability. Oral delivery of injectable peptides is a genuinely active problem, and semaglutide is the model cargo here rather than the object of study. Weight this as early proof-of-concept chemistry; whether it translates to meaningful absorption in vivo is untested.
Plain-language abstract
Semaglutide is normally injected because digestive enzymes break it down if swallowed. In this laboratory study, scientists packed semaglutide together with a natural protein called BBI, which blocks a digestive enzyme, inside tiny hydrogel beads, aiming to protect the drug so it could survive in the gut. In lab tests mimicking digestion, the BBI blocked the enzyme trypsin and roughly extended how long semaglutide lasted in a simulated intestine, from about 2.5 to 4 hours. All of this was done in test tubes, not in animals or people, so it shows the idea can work in principle but not whether the body would actually absorb more of the drug. It is an early engineering step toward possible oral versions of peptide medicines, using semaglutide as a test cargo.